Serological Evidence of Filovirus Infection in Nonhuman Primates in Zambia.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
30 06 2021
Historique:
received: 19 05 2021
revised: 23 06 2021
accepted: 25 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 15 12 2021
Statut: epublish

Résumé

Ebolaviruses and marburgviruses are filoviruses that are known to cause severe hemorrhagic fever in humans and nonhuman primates (NHPs). While some bat species are suspected to be natural reservoirs of these filoviruses, wild NHPs often act as intermediate hosts for viral transmission to humans. Using an enzyme-linked immunosorbent assay, we screened two NHP species, wild baboons and vervet monkeys captured in Zambia, for their serum IgG antibodies specific to the envelope glycoproteins of filoviruses. From 243 samples tested, 39 NHPs (16%) were found to be seropositive either for ebolaviruses or marburgviruses with endpoint antibody titers ranging from 100 to 25,600. Interestingly, antibodies reactive to Reston virus, which is found only in Asia, were detected in both NHP species. There was a significant difference in the seropositivity for the marburgvirus antigen between the two NHP species, with baboons having a higher positive rate. These results suggest that wild NHPs in Zambia might be nonlethally exposed to these filoviruses, and this emphasizes the need for continuous monitoring of filovirus infection in wild animals to better understand the ecology of filoviruses and to assess potential risks of outbreaks in humans in previously nonendemic countries.

Identifiants

pubmed: 34209295
pii: v13071283
doi: 10.3390/v13071283
pmc: PMC8309988
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Emerg Microbes Infect. 2020 Dec;9(1):124-128
pubmed: 31913767
J Virol Methods. 2011 Jan;171(1):310-3
pubmed: 21093485
J Epidemiol Glob Health. 2018 Dec;8(3-4):162-170
pubmed: 30864758
Clin Vaccine Immunol. 2010 Nov;17(11):1723-8
pubmed: 20861331
Ecohealth. 2016 Jun;13(2):405-9
pubmed: 27138290
One Health Outlook. 2020;2(1):16
pubmed: 32835170
PLoS Negl Trop Dis. 2014 Sep 18;8(9):e3143
pubmed: 25232832
Emerg Infect Dis. 2019 May;25(5):911-918
pubmed: 31002071
J Gen Virol. 2013 Jun;94(Pt 6):1357-1364
pubmed: 23426354
J Infect Dis. 2004 Dec 1;190(11):1895-9
pubmed: 15529251
J Infect Dis. 2015 Oct 1;212 Suppl 2:S101-8
pubmed: 25786916
Int J Infect Dis. 2020 Oct;99:233-242
pubmed: 32758690
Lancet. 1992 Aug 22;340(8817):451-3
pubmed: 1354784
Microbes Infect. 2005 Jun;7(7-8):1005-14
pubmed: 16002313
Arch Virol. 2020 Dec;165(12):3023-3072
pubmed: 32888050
Science. 2004 Jan 16;303(5656):387-90
pubmed: 14726594
Clin Microbiol Rev. 2016 Oct;29(4):773-93
pubmed: 27413095
J Infect Dis. 2018 Jan 30;217(4):529-537
pubmed: 29329455
Lancet. 1995 May 20;345(8960):1271-4
pubmed: 7746057
J Infect Dis. 2018 Nov 22;218(suppl_5):S312-S317
pubmed: 29889270
Am J Primatol. 2010 Jun;72(7):634-44
pubmed: 20213654
Emerg Infect Dis. 2013;19(9):
pubmed: 23968816
J Infect Dis. 2019 Oct 8;220(10):1599-1608
pubmed: 30657940
Science. 2009 Jul 10;325(5937):204-6
pubmed: 19590002
Science. 2006 Dec 8;314(5805):1564
pubmed: 17158318
Mov Ecol. 2015 Jul 01;3(1):14
pubmed: 26137307
Parasit Vectors. 2014 Oct 29;7:490
pubmed: 25358853
Trans R Soc Trop Med Hyg. 1982;76(3):307-10
pubmed: 6810518
Emerg Infect Dis. 2019 Aug;25(8):1577-1580
pubmed: 31146800
J Virol. 2013 Mar;87(5):2608-16
pubmed: 23255795
Curr Top Microbiol Immunol. 2017;411:3-21
pubmed: 28766193
PLoS One. 2012;7(7):e40740
pubmed: 22815803
J Infect Dis. 1999 Feb;179 Suppl 1:S120-6
pubmed: 9988175
Lancet. 1990 Mar 3;335(8688):502-5
pubmed: 1968529
Am J Primatol. 1982;3(1-4):41-53
pubmed: 31991989
PLoS Negl Trop Dis. 2020 Oct 23;14(10):e0008799
pubmed: 33095771
J Infect Dis. 1992 Oct;166(4):753-63
pubmed: 1527410

Auteurs

Katendi Changula (K)

Department of Paraclinical Studies, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia.

Edgar Simulundu (E)

Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia.
Macha Research Trust, P.O. Box 630166, Choma 20100, Zambia.

Boniface Pongombo Lombe (BP)

Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.
Central Veterinary Laboratory of Kinshasa, Kinshasa BP 8842, Democratic Republic of the Congo.
Faculty of Veterinary Medicine, National Pedagogic University, Kinshasa BP 8815, Democratic Republic of the Congo.

Eri Nakayama (E)

Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-0052, Japan.

Hiroko Miyamoto (H)

Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.

Yuji Takahashi (Y)

Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.

Hirofumi Sawa (H)

Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia.
Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.
International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.

Chuma Simukonda (C)

Department of National Parks and Wildlife, Chilanga 10101, Zambia.

Bernard M Hang'ombe (BM)

Department of Paraclinical Studies, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia.

Ayato Takada (A)

Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia.
Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.
International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH